{"id":369614,"date":"2023-12-25T00:01:00","date_gmt":"2023-12-24T23:01:00","guid":{"rendered":"https:\/\/medizinonline.com\/les-modulateurs-cftr-rendent-les-poumons-heureux\/"},"modified":"2023-11-13T09:44:41","modified_gmt":"2023-11-13T08:44:41","slug":"les-modulateurs-cftr-rendent-les-poumons-heureux","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/les-modulateurs-cftr-rendent-les-poumons-heureux\/","title":{"rendered":"Les modulateurs CFTR rendent les poumons heureux"},"content":{"rendered":"\n<p><strong>On sait que les modulateurs CFTR<em> (cystic fibrosis transmembrane conductance regulator) <\/em>am\u00e9liorent les maladies pulmonaires associ\u00e9es \u00e0 la fibrose kystique (CF). Cependant, les effets des th\u00e9rapies CFTR sur les changements structurels des poumons des patients atteints de mucoviscidose ne sont pas clairs. Des chercheurs am\u00e9ricains ont donc voulu d\u00e9terminer l&#8217;impact sur les param\u00e8tres cliniques et la maladie pulmonaire structurelle, mesur\u00e9 par les modifications des scanners thoraciques, chez les personnes atteintes de mucoviscidose.<\/strong><\/p>\n\n<!--more-->\n\n<p>Le pourcentage pr\u00e9dit du VEMS (ppFEV1), l&#8217;IMC et les donn\u00e9es microbiologiques ont \u00e9t\u00e9 recueillis au d\u00e9but du traitement par Elexacaftor\/Tezacaftor\/Ivacaftor (ETI) et tous les trois mois pendant un an, a expliqu\u00e9 le Dr Shahid I. Sheikh, pneumologue p\u00e9diatrique, d\u00e9partement de p\u00e9diatrie, Nationwide Children&#8217;s Hospital, Columbus, Ohio, dans sa pr\u00e9sentation par affiche [1]. Des tomodensitogrammes de la cage thoracique ont \u00e9t\u00e9 r\u00e9alis\u00e9s avant le d\u00e9but du traitement par ETI (ligne de base) et apr\u00e8s un an, et analys\u00e9s ind\u00e9pendamment par deux pneumologues.<\/p>\n\n<p>L&#8217;\u00e9chantillon comprenait 67 patients atteints de mucoviscidose, dont 30 (44,8%) hommes, \u00e2ge m\u00e9dian 25 ans. Apr\u00e8s 3 mois, une augmentation significative de la <sub>ppFEV1<\/sub> (65\u00b121 \u00e0 77\u00b121) et de l&#8217;IMC (p&lt;0,001 pour les deux) a \u00e9t\u00e9 observ\u00e9e, ainsi qu&#8217;une diminution significative de la positivit\u00e9 du SARM et du Pseudomonus (-42% pour les deux). Cette tendance s&#8217;est maintenue pendant plus d&#8217;un an. Aucun des participants n&#8217;a d\u00e9velopp\u00e9 de d\u00e9t\u00e9rioration des param\u00e8tres du scanner thoracique pendant le traitement par ETI. Au d\u00e9but du traitement, les scanners thoraciques ont r\u00e9v\u00e9l\u00e9 une bronchectasie chez 65 patients (97%) ; lors du suivi \u00e0 1 an, elle a disparu ou a \u00e9t\u00e9 r\u00e9duite chez 17% d&#8217;entre eux. Un \u00e9paississement de la paroi bronchique a \u00e9t\u00e9 constat\u00e9 chez 64 (97%) \u00e0 la ligne de base, et apr\u00e8s 12 mois, il n&#8217;\u00e9tait plus pr\u00e9sent ou avait diminu\u00e9 chez 58 (86%). Une congestion du mucus a \u00e9t\u00e9 constat\u00e9e chez 63 (95,5%), elle n&#8217;\u00e9tait plus pr\u00e9sente ou avait diminu\u00e9 chez 61 (95%) apr\u00e8s 1 an. L&#8217;hyperinflation\/le trappage a\u00e9rien \u00e9taient pr\u00e9sents chez 44 (67%) personnes au d\u00e9part, ils \u00e9taient moins pr\u00e9sents ou absents chez 38 (61%) apr\u00e8s 1 an et inchang\u00e9s chez 24 (39%).<\/p>\n\n<p>Le traitement ETI a donc am\u00e9lior\u00e9 de mani\u00e8re significative les r\u00e9sultats cliniques et la maladie pulmonaire, comme l&#8217;ont montr\u00e9 les scanners thoraciques, ont conclu le Dr Sheikh et ses coll\u00e8gues.<\/p>\n\n<p>Source :<\/p>\n\n<ol class=\"wp-block-list\">\n<li>Sheikh SI : Pr\u00e9sentation du poster 1541 ; ERS Congress 2023, Milan, 10.09.2023.<\/li>\n<\/ol>\n\n<p class=\"has-small-font-size\"><em>InFo PNEUMOLOGIE &amp; ALLERGOLOGIE 2023 ; 5(4) : 32 (publi\u00e9 le 8.11.23, ahead of print)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On sait que les modulateurs CFTR (cystic fibrosis transmembrane conductance regulator) am\u00e9liorent les maladies pulmonaires associ\u00e9es \u00e0 la fibrose kystique (CF). Cependant, les effets des th\u00e9rapies CFTR sur les changements&hellip;<\/p>\n","protected":false},"author":7,"featured_media":369616,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Fibrose kystique ","footnotes":""},"category":[11527,11477,11535,11549],"tags":[15491,72135,12169,15496,12171,72136],"powerkit_post_featured":[],"class_list":["post-369614","post","type-post","status-publish","format-standard","has-post-thumbnail","category-etudes","category-pneumologie-fr","category-rapports-de-congres","category-rx-fr","tag-cf-fr","tag-cftr-fr","tag-fibrose-kystique","tag-fibrose-kystique-fr","tag-modulateurs-cftr","tag-regulateur-de-conductance-transmembranaire-de-la-mucoviscidose","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-02 16:27:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":369642,"slug":"i-modulatori-della-cftr-rendono-felici-i-polmoni","post_title":"I modulatori della CFTR rendono felici i polmoni","href":"https:\/\/medizinonline.com\/it\/i-modulatori-della-cftr-rendono-felici-i-polmoni\/"},"pt_PT":{"locale":"pt_PT","id":369653,"slug":"os-moduladores-da-cftr-fazem-os-pulmoes-felizes","post_title":"Os moduladores da CFTR fazem os pulm\u00f5es felizes","href":"https:\/\/medizinonline.com\/pt-pt\/os-moduladores-da-cftr-fazem-os-pulmoes-felizes\/"},"es_ES":{"locale":"es_ES","id":369690,"slug":"los-moduladores-de-cftr-alegran-los-pulmones","post_title":"Los moduladores de CFTR alegran los pulmones","href":"https:\/\/medizinonline.com\/es\/los-moduladores-de-cftr-alegran-los-pulmones\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/369614","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=369614"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/369614\/revisions"}],"predecessor-version":[{"id":369617,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/369614\/revisions\/369617"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/369616"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=369614"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=369614"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=369614"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=369614"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}